A Phase III, Multi-center, Randomized, Double-blind, 48 Week Study With an Initial 12 Week Placebo-controlled Period to Evaluate the Safety and Efficacy of Osilodrostat in Patients With Cushing's Disease
Phase of Trial: Phase III
Latest Information Update: 20 Nov 2017
At a glance
- Drugs Osilodrostat (Primary)
- Indications Pituitary ACTH hypersecretion
- Focus Registrational; Therapeutic Use
- Acronyms LINC-4
- Sponsors Novartis; Novartis Pharmaceuticals
- 16 Oct 2017 Planned End Date changed from 22 Nov 2019 to 25 Oct 2019.
- 16 Oct 2017 Planned primary completion date changed from 22 Nov 2019 to 25 Oct 2019.
- 04 Apr 2017 Trial design presented at The 99th Annual Meeting of the Endocrine Society